




T1International

Our Impact in 2021





T1International

Our Impact in 2021

Thank you	03
2021: Mobilising for change	04
2021: Highlights	08
2021: Key moments	09
Bringing the voices of people living with diabetes to the WHO's Global Diabetes Compact	10
Launching the 100 Years: From Gift to Greed campaign	12
Supporting Advocates and Chapters to create change in their communities	13
Successfully protecting Alec Smith's Law in Minnesota	14
Securing the addition of long-acting insulin analogues to the WHO's Essential Medicines List	16
Pushing for more insulin provisions as part of the Build Back Better Act	18
Lessons to take forward in 2022	19
Our team	23
Our finances	30

Thank you.

We are so grateful to all of our donors, supporters and volunteers who made our work in 2021 possible. Thanks to the hard work and generosity of so many, 2021 was our most impactful year yet. We were able to bring people together to influence policy change at the highest levels, while also making insulin and supplies more accessible to communities across the world. We've built on our past successes to create a stronger and more powerful community. All this happened in the midst of an ongoing pandemic that weighed heavily on our team and community.

Despite all the progress we've made, we know that in many ways, we have only just started. Right now, millions of people like me are thinking about insulin. They're thinking about when they might need another dose, whether they will need more supplies in the coming weeks, and how long it would take to get to the hospital if they needed additional care. Those are daunting and stressful thoughts, but those of us who can think like that are actually the privileged few. Millions of people are forced to ration their supplies because of high costs or poor availability. For many, the consequences are severe.

The year 2021 marked a century since the discovery of insulin. Frederick Banting and his fellow researchers sold the patent for \$3 so that insulin could, in his words, "belong to the world". But one hundred years later, that's a gift that has been destroyed because of a market controlled by the 'Big Three' pharmaceutical companies who prevent competition, and due to governments and world leaders who have not yet held them accountable. One in every two people who need insulin cannot access or afford it.

T1International is on a mission to change that. In 2021, we marked five years since we were first registered as a charity in the UK, and two years since we set up our 501c3 in the US. We're a young and growing community of patients, carers, partners, and allies focused on supporting people living with diabetes to advocate for their rights to insulin and the supplies they need to live full and healthy lives. We continue to be energised by the far-reaching and dedicated community of advocates with whom we work. They are the backbone of our non-profit organisations in the US and the UK. This report serves to highlight just some of the work which has been possible thanks to them, and thanks to the generosity and commitment of our partners, funders, and volunteers.

With our community of supporters by our side, we believe we can ensure insulin belongs to the world in our lifetime. Together, we know that we can achieve #insulin4all. If you would like to learn more, I encourage you to reach out to us for a conversation.

With hope and gratitude,

A handwritten signature in blue ink that reads "Liz".

Elizabeth Pfiester
Founder & Executive Director

Where you are born should not determine whether you live or die from diabetes

T1International believes that where you are born should not determine whether you live or die from diabetes. However, today 1 out of every 2 people in need of insulin cannot access or afford it. As a non-profit organisation founded and led by people living with diabetes, we bring the experiences and voices of our peers to the heart of the organisation and to the global advocacy agenda.

In 2021, we continued to support communities, providing advocates with tools to help them stand up for their rights in service of our vision for a world where everyone with type 1 diabetes - no matter where they live - has everything they need to survive and thrive. This includes reliable access to insulin and other essential diabetes supplies like syringes, ketone strips, and glucagon injections, as well as access to relevant support, networks, and education.

To achieve our goals in 2021, we continued to refine our focus on three key areas.

Grassroots Advocacy

We educated and supported advocates worldwide, providing volunteers with in-depth training to equip them with the skills, knowledge and tools to affect change in their states and regions. Coupled with this training, we supported advocates to create tailored and specific actions plans, contextualised according to local need. By the end of 2021, we were working closely with advocates in 20 countries, and our advocacy resources had been downloaded thousands of times, used in more than 30 countries, and translated into 10 languages.



National Policy Change

Through our advocacy training, we supported individual leaders to bring about change within their own communities, states and countries. Many of them advocated as part of local networks and 'Chapters' of T1International. Through mentoring, advice, and peer-networks we supported groups to develop local advocacy goals and deliverables so they could apply pressure on governments to ensure diabetes remains a priority and key policies and targets are implemented.




A Global Agenda

Throughout 2021, we continued to advocate to make diabetes a priority within the global agenda. The Global Advocacy Network worked with agencies like the World Health Organisation (WHO) and other high-level actors to represent patients and ensure their voices were at the forefront of access to medicines policy-making and guidance. Through submitting testimony at insulin price hearings, and sharing real stories and hard data, we campaigned for price transparency and policies to make insulin universally affordable. Successes included insulin analogues being added to the WHO's Essential Medicines List for the first time and the launch of the WHO's Global Diabetes Compact.



Photos • Shelsea Deng, speaker at our annual #insulin4all advocacy workshop • T1International #insulin4all vigil in Indianapolis • Lejla, Global Advocate from Bosnia & Herzegovina

We now have 40 Chapters across the US and held over 60 Chapter meetings in 2021.



Globally, in 2021 we were able to support Chapters, Partners and Global Advocates across more than 20 countries through our Global Advocacy Network.

Global Advocates

Volunteers located outside the US wishing to learn advocacy skills and push for change related to insulin and diabetes treatment access in their country or region.

Global Chapters

Groups of individual volunteers working together under the banner of T1International, to learn advocacy skills and push for change related to insulin and diabetes treatment access in their country or region.


Global Advocacy Partners

Organisations that already have established structures, goals and missions but are part of the Global Advocacy Network. Partners gain advocacy support from T1International and exchange ideas and support with T1International in a mutually beneficial partnership.

2021 Global Advocacy Partners include: Diabète et méchant (France), Diabetes Fighters Trust (India), Diabetes LATAM (Panama), and Meethi Zindagi (Pakistan)

Project Partners

Organisations we work with on very specific, focused and time-bound projects or programmes. For example, The Sonia Nabeta Foundation is a project partner for the Pamoja Advocacy Program.



Year in Review: A Snapshot

Feb • We launched work related to equity, values and strategic planning for the organisation, holding a series of consultative meetings for our key volunteers and partners. **Mar** • Our advocates took part in the World Health Organisation Consultation for People Living with Diabetes • We celebrated the decision of the District Court of Minnesota dismissing PhRMA's challenge to the Alec Smith Insulin Affordability Act. **Apr** • T1International advocates and staff team presented information and testimony at the launch of the World Health Organization's Global Diabetes Compact. **May** • We launched our 100 Years: From Gift to Greed campaign, marking a century since the discoverers of insulin began their research in Toronto. • We submitted evidence from our community to the World Health Organisation's Expert Committee on the Selection and Use of Essential Medicines. **June** • We added our voice in support of the Elijah E. Cummings Lower Drug Costs Now Act in the US. **Aug** • Our advocates in Lebanon shared how they worked with the Ministry of Health to continue subsidising essential diabetes medication. **Sept** • The T1International out-of-pocket cost survey, involving 1,066 respondents from 64 countries, was published in the Journal of Diabetes Research and Clinical Practice • We held T1International's Annual #insulin4all Workshop: Advocate, Don't Celebrate, an opportunity for advocates from around the world to learn from each other, build community, and take action in the fight for #insulin4all. **Oct** • Long-acting insulin analogues were added to the World Health Organisation Model List of Essential Medicines, thanks to dedicated advocacy from our community. **Nov** • We heard from our advocates in Tanzania about their challenges and plans to raise awareness of diabetes with community health workers. **Dec** • Our advocates went to the United States Court of Appeals for the Eighth Circuit in support of upholding Minnesota's Alec Smith Insulin Affordability Act following PhRMA's appeal • Five new patient-led T1International Chapters prepared for their public launches in India, Zimbabwe, the Middle East and North Africa (MENA), Wyoming and Idaho, USA.

12

meetings of the Global Advocacy Network and 4 virtual trainings

13

pieces of state legislation passed through support of patient advocates in the US

37

journal and news articles published that raise awareness of insulin or access issues


41

Digital Advocate volunteers amplifying our message

Our favourite stories and key moments from the past year

In a year of such ongoing uncertainty, our incredible network of inspiring individuals continued to find ways to raise awareness and fight for the rights of people living with diabetes. Together, through advocacy and solidarity, we ensured our voices were heard across regions and at all levels, from local community to global policy-level. Our efforts led to making real change happen. There are so many great stories from the past year — these are a few of our favourites.

Bringing the voices of people living with diabetes to the WHO's Global Diabetes Compact



On the 14th of April 2021, the World Health Organisation (WHO) launched its Global Diabetes Compact. It outlined a new approach to improve diagnosis and care for those with diabetes through influencing policy, creating worldwide action targets, providing support relating to the COVID-19 crisis, and creating a global diabetes price tag.

Crucially, the life experiences of people living with diabetes were heard as part of the development of the Compact. T1International has been a fundamental partner to these efforts. In the months leading up to the Compact's launch, dozens of T1International advocates added their voice, through consultations, workshops, and written commentary. In sharing real-world testimony and data, our

network of advocates from across the globe has helped shape the Compact, ensuring its priorities and recommendations centre on the needs of the community it sets out to serve.

Amongst those who provided testimony are T1International Global Advocates Dani and Apoorva, who shared important insights through speaking at WHO-led multi-stakeholder workshops and consultations. Both Dani and Apoorva now sit on the WHO Diabetes Compact Advisory Panel, serving as representatives of T1International and their own regional communities. Through their positions, they continue to help guide the Compact's work from a patient perspective, working to improve outcomes for our community.


Photo • T1International advocates and patients from around the world share insights at the WHO Consultation on People Living with Diabetes

“I will keep raising my voice to make sure the changes that are needed become a reality. I will keep on pushing, asking the uncomfortable questions, taking a stand and raising my voice to make sure insulin is treated as a right – not a privilege – for those living with type 1 diabetes not only in Latin America but throughout the entire world.”

Dani Rojas
T1International Global Advocate



Launching the 100 Years: From Gift to Greed Campaign



In May, we launched our 100 Years: From Gift to Greed campaign to coincide with the one-hundred-year anniversary of the discovery of insulin.

In 1923, insulin's discoverers won the Nobel Prize for their life-changing work and decided to sell the drug patent for just \$3, eventually passing the rights to pharmaceutical company Eli Lilly and Co. so insulin could be available to all who needed it.

"Insulin does not belong to me, it belongs to the world" — Frederick Banting

While this incredible advancement was intended as a gift, Eli Lilly and the two other major insulin producers, Sanofi and Novo Nordisk, have turned insulin into a profit machine. The unaffordable costs of essential insulin are forcing 1 in 4 people globally to ration their medicine. Capitalising on this important anniversary, the 100 Years campaign

provides a call to action, coupled with tools and guidance, for advocates to raise awareness about extortionate insulin price rises.

As part of the campaign, we worked with [Miss Diabetes](#) on a video that tells the story of insulin's origins and the outrageous reality that 1 in 2 people still can't access or afford their insulin today. That video has been translated into [Spanish](#), [French](#) and [Arabic](#). Advocates have taken action through sharing the campaign press release and social media posts, submitting quotes, and hosting video watch parties.

Over the coming year, we will continue to raise awareness through this campaign to ensure insulin access remains a priority within the public agenda.

[▶ Watch 100 Years: From Gift To Greed](#)

Photo • Illustration by Miss Diabetes, from her animation for the 100 Years: From Gift to Greed campaign video

Supporting Advocates and Chapters to create change



T1International supports advocates and regional 'Chapters', by providing a virtual hub to connect volunteers, and deliver training, guidance and tools, so they can make concrete plans to affect change in their local area.

Today, T1International has advocates in 20 countries across five continents, with a growing number of Chapters across regions. In 2021, T1International's Zimbabwe #insulin4all Chapter was established, led by Laura Munyoro. To facilitate the Chapter's founding and growth, T1International provided a range of support, including delivering advocacy training sessions and tools; developing and presenting tailored advocacy planning templates; facilitating social media activity; and on-going planning and capacity-building guidance. The Zimbabwe #insulin4all Chapter has now drafted specific initiatives to contribute to their goal of a comprehensive national diabetes management

plan and price reduction of insulin. One of the first planned projects is free information sessions including how to access blood glucose tests, signposts for mental health support, and follow-up sessions with those who may need more community support. These sessions will also provide a platform for patients to share stories and to inform on-going priorities.

The Zimbabwe #insulin4all Chapter is already making an impact globally. With our support, Laura recorded a testimonial about the challenges of life with type 1 diabetes in Zimbabwe and the plans the Chapter has developed to address them. Laura's testimonial is featured in our new [Global Advocacy Training \(Basics\)](#)⁷, so advocates in other countries can learn and take inspiration from how Zimbabwe #insulin4all is persevering in the face of corruption and severe access issues.

Photo • Laura Munyoro, Chapter Representative of T1International's Zimbabwe #insulin4all Chapter

Successfully protecting Alec Smith's Law in Minnesota



In April 2020, thanks to months of diligent advocacy by T1International Ambassador Nicole Smith-Holt and the Minnesota #insulin4all Chapter, the Alec Smith Emergency Insulin Bill was signed into law in Minnesota.

Alec's Bill is named for Nicole's son, 26-year-old Alec Smith, who passed away after rationing his insulin in 2017. The legislation provides a safety net supply of insulin for those who need it and long-term protection for low-income individuals. Since its establishment, hundreds of people have been protected.

Insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi immediately and strongly opposed the legislation. Two months after the crucial bill was passed, the pharmaceutical industry trade

group PhRMA filed a lawsuit against the state of Minnesota to overturn it. In response, the Minnesota #insulin4all Chapter, alongside allied partners, worked tirelessly to keep Alec's Law intact, including submitting an Amicus Brief to highlight insulin access difficulties faced by patients and the critical need for Alec's Law.

In March 2021 the District Court of Minnesota dismissed PhRMA's challenge, marking a monumental win for the diabetes advocacy community against Big Pharma.

PhRMA has since appealed the decision, but T1International's volunteers and partners continue to fight with advocacy and solidarity, including the submission of a second Amicus Brief in June 2021, to ensure insulin is accessible to those who need it.

Photo • Nicole Smith-Holt and James Holt Jr speaking outside of Eli Lilly's headquarters in Indianapolis, Indiana

“Access to affordable insulin is a human right and far too many people are denied the right to a happy, healthy life because they simply cannot afford it. Alec’s Law is a crucial step in the right direction which has already protected hundreds of individuals. Going forward, it is vital we continue to fight to keep Alec’s Law intact, standing up against the pharmaceutical industry, to save lives.”

Nicole Smith-Holt
T1International Ambassador



Securing the addition of long-acting insulin analogues to the WHO's Essential Medicines List



2021 saw the World Health Organisation (WHO) add long-acting insulin analogues to its Essential Medicines List for the first time, marking a significant step for the diabetes community and a monumental win for advocates worldwide.

T1International's Global Advocacy Network played a crucial role in achieving this change, with volunteers and staff around the world submitting testimony in large numbers in support of analogues being added to the list.

Patients across the globe are celebrating this addition, which will increase access to insulin analogues for everyone. The Essential Medicines

List is frequently used by countries to help develop their own local lists of essential medicines. While it is not a law, this list carries a lot of weight globally.

The addition of long-acting analogues is a signal to all governments in the world that this type of insulin is considered essential and is a huge step towards global equity in diabetes treatment. It takes us further away from a tiered health system where the rich get the 'good' insulin and the poor only have access to older, 'worse' types of insulin.

T1International will continue to work to ensure implementation of this addition becomes a reality.

Photo • Long-acting insulin analogues, like Lantus and Semglee, were added WHO's Essential Medicines List

"The way my quality of life and health have improved because of analogue insulin is incomparable. I have experienced my best years with diabetes on analogue insulin rather than the older, less manageable NPH insulin. Analogues are truly a gift to the diabetes world, one that everyone with diabetes deserves to experience."

Yemurai Machirori
T1International Global Advocate



Pushing for more insulin provisions as part of the Build Back Better Act



At T1International, we know the importance of awareness-raising activities to ensure insulin access is at the forefront of policy making. In partnership with [Families United for Affordable Insulin \(FUFAl\)](#)⁷, a T1International group for families who have lost loved ones due to insulin rationing, we have continued to advocate and demand that the US Congress establish a plan to lower drug prices.

In November we placed a mobile digital billboard in Washington DC to honour those who have died due to insulin rationing. We called for change through the lowering of prescription drug costs for Americans to ensure no more lives are so tragically lost because insulin costs too much. On the last day of the billboard's circulation, T1International and FUFAl met with the office of US Congressional Representative

Pramila Jayapal to discuss insulin pricing, providing an opportunity to share further stories to highlight the pressing need and measures required to improve insulin access. With the co-leadership of Representative Cori Bush, this resulted in 97 US Congressional Representatives signing a [letter](#)⁷ in support of strengthening and expanding the insulin provisions in the Build Back Better Act in the Senate.

Thanks to the mobile billboard, we continue to develop increasingly strong relationships with Congress and state legislators. Our bold, uncompromising stance and ability to have policymakers meet directly with those most impacted allows us to input on important legislation, which we hope will lead to federal bills being put forward in 2022.

Photo • T1International's Digital Billboard raises awareness in Washington DC

Lessons to take forward in 2022

We don't ever want to stop learning. We want to be an organisation that listens to the people we work with, the community we serve and the data we gather. In the last year, we've learned a lot. Here are a few of the things we've learned that we want to build into our work in 2022.

1/4

We must take action to address the increasing number of people who need insulin, particularly in the global south.

Despite our progress and knowing that there has been positive change, the scale of the challenge remains enormous.


A century on from the phenomenal discovery of insulin, millions of people still suffer life-changing complications related to diabetes, such as blindness or amputations and, in many cases, an early death. Today, there are approximately 100 million people globally who need insulin. However, half struggle to access this life-saving medication, which can lead to devastating complications and death.

This scandal affects 50 million people and disproportionately affects the world's most vulnerable people, with lack of insulin being the leading cause of death for children with type 1 diabetes.

Across the world, millions of people living with diabetes need insulin:

↗ Numbers of those with type 1 and 2 diabetes in Africa 'could reach 55 million by 2045'¹

↗ India and Pakistan rank in the top 3 countries by diabetes prevalence (type 1 and 2), with COVID-19 intensifying the situation across the region²



2/4

We must continue to adapt to deal with the impact of COVID-19 on people living with type 1 diabetes.

The pandemic has exacerbated the challenges we face, with even more evidence emerging over the course of 2021 about its effect on lives and livelihoods across the world.

Studies show that:

↗ People over the age of 40 with type 1 diabetes were more likely to become hospitalised³ and die after contracting COVID-19⁴

↗ COVID-19 may be leading to an increase in type 1 diabetes⁵

↗ Africa's death rates from COVID-19 infections are significantly higher in patients with diabetes⁶

3/4

We must continue to be led by and push for more and better data.

T1International brought new evidence to emphasise the problems faced by people living with diabetes through our Out-of-Pocket Cost Survey. Published in 2021, this is the most extensive patient-led costs survey for people living with diabetes, with over a thousand responses from patients in 64 countries.

The survey fills a gap in much needed data to support the hundreds of real-life stories we hear every year about struggles with the high costs related to diabetes.

“The pandemic has made it difficult to access the doctors I need to get prescriptions. I have insulin insecurity, and I frequently [choose] to not eat so I won’t waste insulin on food. I worry that not having insulin would be a financial burden on my family and friends.”

—Survey respondent from the USA


As we look ahead, we will continue to use this information to guide our own priorities and to inform advocates, partner organisations and policymakers, to ensure actions are reflective of the needs of the global diabetes community.

Key findings include:


↗ Worldwide, one out of every four respondents reported having underused their insulin at least once in the last year due to high costs

↗ 25% of participants reported an increase of insulin prices related to the COVID-19 pandemic

↗ 63% of participants reported disruption of insulin supplies related to the COVID-19 pandemic



↗ 69% of respondents from Ghana reported rationing test strips at least once per week



↗ Participants from Guatemala reported the highest average monthly out of pocket costs for diabetes at \$768 per month, followed by the Dominican Republic (\$603), Jordan (\$570), and the US (\$490)

4/4

We will continue to be led by our community of people living with and impacted by diabetes.

T1International is committed to ensuring our values and goals reflect the needs of the community we serve. In 2021, we conducted a consultative process, inviting feedback from more than 80 volunteers, partners and advocates, through a range of channels including written surveys, focus groups and meetings without staff present. The consultation included intentional deep listening to people of colour from our community.

Through this process, we set out a number of aspirational values, representing what and how we desire to be as an organisation. We also built out a dashboard that detailed key strategic goals by which we can measure how we are embodying them.

T1International's values:

Patient-led
Independent
Transparent

Inclusive
Bold
Hopeful

These values serve to inspire us and hold us accountable. They are the basis and underpinning of our two year strategic goals dashboard.



Photo • Coral Deng wearing her #insulin4all t-shirt

Our Team

With the addition of several new staff members we've brought in a group of extremely talented and dedicated people to our team. We grew from 8 to 12 staff in the last year, across the US and UK.

T1International is a registered charity in England and Wales and T1International USA is a registered 501(c)(3) organisation based in the United States. The US team focuses on state and national level mobilisation and advocacy throughout the US, while the team in the UK is well placed to support global initiatives. The two entities are distinct, but work together with the same mission and vision, bringing together local and national efforts across the world so that we collaborate as one movement for change.

Our Global Team

Elizabeth

Founder & Executive Director



Elizabeth Pfister was born in the US and has lived with type 1 diabetes for 30 years. She completed her Master's degree in International Development at the London School of Economics and Political Science and has a background with non-profits, diabetes and health organisations. Elizabeth believes that by working together, we can achieve #insulin4all.

Katie

Global Advocacy Consultant



Katie Souris has lived with type 1 diabetes for the past 15 years. With a Master's degree in Public Health and professional background in diabetes-focused health interventions and type 1 diabetes research, Katie strongly aligns with T1International's vision and values.

Tolu

Supporter Engagement Coordinator



Tolu Jean-Jules was born in Nigeria, raised in England, and has lived in the US. Her passion for advocacy comes from managing type 1 diabetes for 24 years within 3 very different socioeconomic and healthcare systems.

Chloe

Development Director



Chloe Moorhead has over 13 years of experience in fundraising and communications. She specialises in building and implementing sustainable income strategies for charities, especially within the health sector.

Beth

Operations Coordinator



Beth Edwards has lived with type 1 diabetes for 24 years. She completed an MSc in health psychology and has worked in academic health research for several years before launching her own nutrition clinic that supports people with type 1 to find their balance.

Our US Team

Allison

Advocacy Manager



Allison Hardt has worked in non-profits for the past decade, with a focus on relationship-building, programme development and organisational advancement. Her partner, who has been living with type 1 diabetes since childhood, inspires her advocacy work every day.

Fiona

National Director



Fiona Mason is a social worker whose roles have intersected with a wide range of social justice issues from homelessness to immigration to human trafficking. Regardless of the population focus, the need for a public health response is evident, starting with insulin and healthcare for all.

Arika

Development Manager



Arika has worked in non-profit development for six years and is a fervent advocate for equitable and accessible healthcare for all. Her research and work around reproductive justice in the D.C. Metro Area has framed her understanding that access to resources and care are human rights.

Ian

Communication Coordinator



Ian Devaney was diagnosed with type 1 diabetes as an adult. His passion is to support and empower the next generation of people with diabetes with the knowledge and technology that has made his life possible.

Liz

Programme Coordinator



Liz Stuewe has lived with type 1 diabetes since she was 13 and her experiences have shaped her into a passionate advocate for the health and safety of all people.

Kate

Operations Manager



Kate Pidwerbecki has worked in operations management for the past ten years, providing support to non-profits, educational, and social justice organisations. Having lived with type 1 diabetes since she was 10, she is a firm believer that access to insulin is a human right.

Shaina


Policy Manager



Shaina Kasper is an experienced strategist and organiser whose work has stopped pipeline proposals, regulated toxic chemicals in drinking water, raised the minimum wage, and more. Having lived with type 1 diabetes since 2021, Shaina is proud to implement policy change for people living with diabetes.

Jesus

Advocacy Manager



Jesus Morales Sanchez has lived with type 1 diabetes since 2018. Jesus is a queer, Latinx immigrant from Mexico with a passion for art, science and advocacy. He was previously a Lead for Connecticut #insulin4all and has worked to push for change for immigrant communities.

UK and USA Board Chair

Fiona Conner

Fiona Conner owns and runs a price comparison website, with varied experience from biotechnology to web projects. Her daughter developed type 1 diabetes at the age of three. Fiona grew up in a developing country and has first-hand experience of under-resourced healthcare.

UK Charity Board Members

Anbreen Slama-Chaudhry

Anbreen Slama-Chaudhry is a medical doctor who specialises in primary care, chronic disease management, patient therapeutic education, and public health. Born in Pakistan, she was raised in Geneva, where she graduated and has worked as a General Practitioner for 15 years.

Olamide Adejumo

Olamide Adejumo is a Nigerian Licensed Medical Doctor and a pioneer voice on social media diabetes advocacy in Nigeria. Olamide was the co-founder and director of operations of The Nigeria Diabetes Online Community until 2019.

UK and US Board Members

Cameron J. Hall

Cameron J. Hall is a higher education advancement and development professional who specialises in marketing strategies. He has more than ten years of non-profit management experience and higher education and fundraising experience. Cameron was diagnosed with type 1 diabetes in 1999.

Kim Carter Martinez

Kim Carter Martinez grew up in New Jersey with a mum who had type 1 diabetes. Her mum died when she was 17 years old and when she was 19 she herself was diagnosed with diabetes and has been thriving with it ever since. In her professional life Kim is the political and legislative director of a labour union.

Heather Robinson

Heather Robinson is a CPA and certified internal auditor, with 30 years' experience in government and non-profit organisations. She recently retired from the staff of the Board of Governors of the Federal Reserve System. Heather is acutely aware of the issues with and limitations of the US healthcare system because her daughter has had type 1 diabetes since age 13.

Matthew Dinger

Matthew Dinger is a healthcare technology executive who has been working in global health and patient experience for over a decade. He developed type 1 diabetes at the age of five which has shaped the way he views healthcare personally as well as professionally.

US Board Members

Melissa Passarelli, MA

Melissa Passarelli, MA, was diagnosed with type 1 diabetes in 1999, and has since been an advocate for the diabetes community, most recently as part of the Lead team for the New York #insulin4all Chapter. Her background is rooted in the non-profit sphere, having trained in mental health and public policy and worked with organisations that focus on providing equal opportunities regardless of circumstance.

Erin Worbs

Erin Worbs is an attorney who operates her own law firm focusing primarily on advising small businesses and non-profits. Erin has done volunteer non-profit fundraising and legislative advocacy for several years. She became passionate about supporting #insulin4all after previously working as a social security disability attorney and seeing the destructive consequences that come from the inaccessibility of insulin and care in the American healthcare system.

Our Ambassador

Nicole Smith-Holt

Nicole Smith-Holt is the mother of Alec, who passed away because he was rationing his insulin.

"I share my story of Alec's life and death to prevent other families from going through what my family did. I believe everyone has a right to affordable healthcare and medications. I look forward to a day when I no longer need to stand before a room of our elected officials and retell the story of my son's death. I fight for the day when insulin insecurity no longer exists, and I am proud to advocate with T1International."

Our Finances

Every financial decision we make, and every penny we spend, is focused on our mission and our work to support advocates around the world. In 2021 we supported critical programmes and made important investments in the capacity of the organisation to deliver on our vision and mission.

Our fundraising promise

In order to deliver and sustain our mission and vision of #insulin4all, T1International actively raises funds from a variety of sources including individuals, companies and grant giving bodies. In raising funds, it is critically important to us and our community that we maintain our independence, credibility, integrity and vision. As long as we exist, T1International will remain committed to our decision to never accept funding from pharmaceutical companies and organisations linked either directly or indirectly with them.

We have a strict policy to ensure this commitment is upheld. This policy outlines that funds raised must benefit people living with diabetes in line with our mission and values, without risk of influencing our policies, activities or decisions, or threatening our independent voice. In addition, in-line with our policy, we will not accept funding from sources where there is any link to products or services that harm or discriminate against people with diabetes or any other individual or group.

We are grateful to our partners, funders, donors and volunteers who enable us to carry out our crucial work whilst maintaining our independence.




**Arnold
Ventures**



ITPC Global (through the Robert Carr Foundation)
Caroline Levins
David Fraser
Domenick Gilio
Michael Harney and Harney Teas
Noah Averbach-Katz
Roger Jones and the Lippincott Jones Family Foundation
Tom at TypeOneTalks

Our US figures relate to funds raised, managed and spent through T1International USA, a tax-exempt organization (EIN: 84-2544817) under section 501(c)(3) of the United States Internal Revenue Code.


US Income		US Expenditure	
A. Grants	\$978,500	D. Direct Programme Costs	\$499,582
B. Individuals	\$111,709	E. Core Staff Costs	\$158,997
C. Retail and Company Giving	\$14,289	F. Operational Costs	\$248,888*
\$1,104,489		\$905,218	



Direct Programme Costs: All costs associated with the delivery of our advocacy programme including staff, materials, events and consultancy.

Core Staff Costs: All internal staff costs that keep our organisation running and enable our programme team to do their work, including roles in operations, communications and fundraising/development.


Operational Costs: All other necessary costs such as travel, insurance, subscriptions and printing.



* As a pivotal year for our US entity, the first full year functioning as a 501(c)(3), there were some key one-off strategic projects undertaken which account for over \$100k of the operational costs in this year. These included: working with consultants to build out our Strategic Goals Dashboard, working on our Case for Support and Impact Report, grant prospecting, and working with a Human Resources consultant to support our organisation's growth from 0 to 8 staff members.

Our global figures relate to funds raised, managed and spent through T1International based in the UK, Charity Commission registration number 1168249.

Global Income		Global Expenditure	
A. Grants	£197,344	D. Direct Programme Costs	£126,980
B. Individuals	£59,455	E. Core Staff Costs	£69,358
C. Other	£518	F. Operational Costs	£8,877
£257,317		£205,215	



Endnotes

1. <https://www.scidev.net/sub-saharan-africa/news/diabetes-in-africa-could-reach-55mln-by-2045/>
2. <https://www.aa.com.tr/en/health/south-asia-faces-alarming-diabetes-surge-amid-covid-19/2419869>
3. <https://www.endocrine.org/news-and-advocacy/news-room/2021/people-over-40-with-type-1-diabetes-and-covid-are-more-likely-to-be-hospitalized>
4. [https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762\(21\)00082-X/fulltext](https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762(21)00082-X/fulltext)
5. <https://www.pharmaceutical-technology.com/comment/type-1-diabetes-covid-19-ripple-effects/>
6. <https://reliefweb.int/report/world/covid-19-more-deadly-africans-diabetes>

Contact

If you have any questions or want to find out how you can get involved please reach out to us at:





contact@t1international.com

Cover Design

In 2021, T1International held a Digital Demonstration to highlight the severity of the global insulin crisis and the fact that 100 years after its discovery, one in two people worldwide can't reliably access or afford insulin. Hundreds of people submitted photos and educated their community about the insulin price crisis. The front and back cover of this report highlights some of the powerful patient advocates who participated.

Front Cover • (Left column, top to bottom) Coral, Madi, and Isabella • (Middle column, top to bottom) Abby, Anna, and Alex • (Right column, top to bottom) Yemurai, Noah, Mariana, and Tinotenda.

Back Cover • (Left column, top to bottom) Jesus, Sabella, Nikki, and Diana • (Middle column, top to bottom) Ash, Beth, and Tolu • (Right column, top to bottom) Allison and Ev, Donia, Ian, and Larry.



T1International is a registered charitable incorporated organisation (CIO) in England and Wales (1168249).

T1International USA is a tax-exempt organization (EIN: 84-2544817) under section 501(c)(3) of the United States Internal Revenue Code.

t1international.com